Accelerated assessment in EU for Boehringer's nintedanib

Boehringer Ingelheim GmbH (Ingelheim, Germany) said EMA accepted for review and granted accelerated assessment to an MAA for nintedanib ( BIBF 1120) to treat idiopathic pulmonary fibrosis (IPF). An accelerated assessment shortens the review period to 150 days from 210. The small molecule inhibitor of multiple pro-angiogenic kinases is also under review in Europe to treat advanced, metastatic or recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma histology. ...